APA (7th ed.) Citation

Anastasia Navitski, Duaa H. Al-Rawi, Ying Liu, Maria M. Rubinstein, Claire F. Friedman, Raajit K. Rampal, . . . Roisin E. O'Cearbhaill. (2021). Baseline risk of hematologic malignancy at initiation of frontline PARP inhibitor maintenance for BRCA1/2-associated ovarian cancer. Elsevier.

Chicago Style (17th ed.) Citation

Anastasia Navitski, Duaa H. Al-Rawi, Ying Liu, Maria M. Rubinstein, Claire F. Friedman, Raajit K. Rampal, Diana L. Mandelker, Karen Cadoo, and Roisin E. O'Cearbhaill. Baseline Risk of Hematologic Malignancy at Initiation of Frontline PARP Inhibitor Maintenance for BRCA1/2-associated Ovarian Cancer. Elsevier, 2021.

MLA (9th ed.) Citation

Anastasia Navitski, et al. Baseline Risk of Hematologic Malignancy at Initiation of Frontline PARP Inhibitor Maintenance for BRCA1/2-associated Ovarian Cancer. Elsevier, 2021.